While audits are part of doing business in the ordinary course, businesses are generally less than eager to open the books. And the same is true when it comes to the 340B Drug Pricing Program. Audits ...

HRSA is piloting a back-end rebate model despite CEs and numerous trade associations having raised significant legal, administrative and financial concerns with shifting a discount program to a rebate ...

On April 28, AEI’s Kirsten Axelsen hosted the former North Carolina Department of Health and Human Services Secretary Kody Kinsley; Anthony DiGiorgio of the University of California, San Francisco; ...

Johnson & Johnson has decided to terminate implementation of its 340B rebate plan, according to an internal email 340B Health shared with Becker’s. In late August, the drugmaker planned to replace ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...

A federal court has struck down a 12-year-old Health Resources and Services Administration policy that restricted how certain 340B hospitals could make initial drug purchases, finding that the agency ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara and Novo Nordisk’s Novolog. The Trump administration announced in August ...

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program ...

Add Yahoo as a preferred source to see more of our stories on Google. In a recent opinion piece, it was suggested the federal 340B Drug Pricing Program is contributing to rising employer health-care ...

Michigan's 340B Drug Pricing Program, meant to help vulnerable patients, is being misused by hospitals, impacting care access.